Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Income towards Parent Company: 2018-2019

Historic Income towards Parent Company for DiaMedica Therapeutics (DMAC) over the last 2 years, with Dec 2019 value amounting to -$2.5 million.

  • DiaMedica Therapeutics' Income towards Parent Company fell 26.40% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 85.72%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.12% down from last year.
  • Latest data reveals that DiaMedica Therapeutics reported Income towards Parent Company of -$2.5 million as of Q4 2019, which was down 1.31% from -$2.4 million recorded in Q3 2019.
  • DiaMedica Therapeutics' Income towards Parent Company's 5-year high stood at -$650,000 during Q1 2018, with a 5-year trough of -$3.3 million in Q1 2019.
  • Over the past 2 years, DiaMedica Therapeutics' median Income towards Parent Company value was -$2.2 million (recorded in 2018), while the average stood at -$2.0 million.
  • Data for DiaMedica Therapeutics' Income towards Parent Company shows a maximum YoY tumbled of 400.31% (in 2019) over the last 5 years.
  • DiaMedica Therapeutics' Income towards Parent Company (Quarterly) stood at -$2.0 million in 2018, then dropped by 26.40% to -$2.5 million in 2019.
  • Its Income towards Parent Company stands at -$2.5 million for Q4 2019, versus -$2.4 million for Q3 2019 and -$2.5 million for Q2 2019.